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1 INTRODUCTIONThe competitiveness in current globalised markets request industrial companies tomanage more efficiently the available manufacturing resources, so as to ensure high levelsof responsiveness under high production variability. The case of the pharmaceuticalindustry is a good example on how market is driving the change on product developmentand manufacturing. This sector is exploring the development of highly effectivebioengineered drugs for the treatment of diseases such as cancer, autoimmune disorders,organ transplant rejection, and many other new drugs are in clinical trials. With thenumber of biologic drugs increasing, manufacturers are being prompted to find flexible,cost-efficient and environmentally feasible solutions for global scales of production. Totackle these challenges, the adoption of decision-support tools have been outspreadedfrom the management of the research and development (R&D) drug portfolio to theoptimal design/operation of biopharmaceutical facilities (Ramasamy et al., 2014).In what concerns the operations management, planning and scheduling decision-makinghas become an essential issue to the majority process industries. The increasingcomplexity in managing batch/continuous processes caught the interest of the research
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community to develop efficient modelling approaches to promote operationalperformance. Several industrial applications of scheduling models have been quitesuccessfully implemented, as stated by Harjunkoski et al. (2014) and Moniz et al. (2014b).Still, despite the major research developments reported in the literature, theimplementation of such models to solve real industrial problems often stumbles, in eithermodelling specific operational requirements or tackling large planning horizons,constrained by the inherent computational complexity. The development of optimisationtools capable to solve real large-scale industrial problems remains a challenge and newformulations for modelling complex process constraints are required, aiming theintegration with common decision-making systems. In the particular case of thebiopharmaceutical industry, the development of models for production planning andscheduling of biopharmaceutical processes is acknowledged that has been fairlyunexplored.In this paper, we tackle this important problem and propose the development of acampaign planning/scheduling model addressing several operational constraints of thebiopharmaceutical processes, such as: a) batch and continuous tasks; b) multipleintermediate deliveries, c) sequence-dependent changeovers; d) product shelf-lifelimitations; e) regulatory track-control of the production/campaign lots. To the best of ourknowledge, very little work has addressed the bioprocessing context, notwithstanding theapplication of some of these operational features to other planning and schedulingproblems. A mathematical formulation is proposed to model these operationalrequirements and two literature-based industrial problems are solved. A resultscomparison is performed with a literature model considering different time modellingapproaches (discrete versus continuous-time), highlighting the performance advantages ofthe proposed formulation. The remainder of the paper is structured as follows: the nextsection presents the background in biopharmaceutical planning/scheduling optimisation;section 3 introduces the problem definition and presents the mathematical modelformulation; in section 4, two problems are presented and discussed regarding itsnumerical results; finally, section 5 summarises the main conclusions and future work.
2 BACKGROUND
2.1 (Bio)Pharmaceutical planning/scheduling optimisationBiopharmaceutical drugs refer to complex medicinal biomolecules with pharmacologicalactivity used for therapeutic or in vivo diagnostic purposes. The ability to geneticallymanipulate (by recombinant DNA or hybridoma technology) highly effective biotherapiessuch as vaccines, cell or gene therapies, therapeutic proteins hormones, monoclonalantibodies, cytokines and tissue growth factors, has represented a breakthrough in thepharmaceutical industry. The biotech sector has been increasing steadily with a strongpipeline of drugs under clinical trial, representing in 2010 more than $100 billion in salesworldwide with over than 200 biologics on the market (Walsh, 2010, Mehta, 2008).Since the introduction of recombinant human insulin in the 1980s, these molecules areproduced by means of genetically engineered biological organisms other than directextraction from native sources. The manufacturing process is generically composed bytwo steps: the upstream processes include all tasks associated with cell culture andmaintenance of the active biological ingredient, and the downstream processes comprisethe chemical/physical operations in the isolation and purification of the drug. The
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primary fermentation stage consists in the inoculation of the target drug from a cell bankin a growth medium, harvested when reached the optimal concentration. The followingpurification procedures typically consider filtration of the source material (suitable forblending product variants), followed by chromatography to select the target proteins. Theproduct is then bulked and stabilised with binding agents according to specifications, fromwhere it is lyophilised to remove water and other solvents. This final product can bestored, packaged and distributed to retail or directly to consumers. In each process stage,product quality control tasks are required to assure process licensure by regulatoryagencies. The same regulatory control is extended to the entire process components,where any change in plant, equipment or process specifications must be certified for eachregion of the world where the product is being sold (Leachman et al., 2014).Most of these manufacturing processes are relatively new and require continuousimprovement due to their long lead times, where the main challenge relies in the largescale production of these biomolecules with a stable output quality. For that reason, themechanisms to produce, purify and preserve the drug have also been subject to researchdevelopment, along with the therapeutic discoveries. The provision of sufficient outputcapacity to meet an expected demand, within the patent protection lifespan and withoutdisregarding all the stringent regulations, resumes the production challenge.The development of planning and scheduling tools are essential in industrialenvironments to maximise production efficiency and resources assignment. Bioprocessautomation has been enhancing the control and monitoring of manufacturing parameters,as reviewed by Junker and Wang (2006), with relevant achievements in applications ofprocess analytical technology (PAT) for quality and performance attributes. But besidesthe manufacturing optimisation, the operations planning ranges from the portfoliomanagement of biopharmaceutical drugs development to the design optimisation modelsfor specific steps of the production process. It is acknowledged that the extended drugdevelopment process and the high uncertainty of the drug’s clinical success commonlyleads to a pipeline of compounds under trial. As example, Rajapakse et al. (2005)developed a prototype decision-making application based on simulation tools, to assist themanagement of the R&D portfolio by accessing both the therapeutic drug developmentactivities and its resources flows, and Farid et al. (2007), Farid et al. (2005) presented the
SIMBIOPHARMA software tool, able to evaluate manufacturing strategies of drugcandidates in terms of cost, time, yield, resource utilisation and risk uncertainty. Whereasaddressing some specific aspects of process design, Brunet et al. (2012) addressed thedesign of upstream/downstream units in a single-product processes with a mixed integerdynamic optimisation and Liu et al. (2015) have proposed significant research work on theoptimisation of downstream chromatography sequencing and column sizing strategies.However, it is noticed a relatively small number of research papers addressing theproduction planning/scheduling of biochemical processes, either encompassing theprocess performance optimisation as well as operating costs, resource utilisation oruncertainties (Vieira et al., 2015). Lakhdar et al. (2005) proposed a discrete time MILPmodel for the optimal production and cost effective planning of manufacturing tasks for amedium term horizon of 1-2 year year and compared with an industrial rule-basedapproach. Then, Lakhdar et al. (2007) addressed a multi-objective long term planninghorizon and Lakhdar and Papageorgiou (2008) considered the uncertainty in operationalparameters, e.g. fermentation titres. More recently, Kabra et al. (2013) developed acontinuous-time multi-period scheduling of a multi-stage multi-product process based onState Task Network framework, Liu et al. (2014) extended a production optimisationmodel to include maintenance planning while considering the performance decay of the
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chromatography resins, Siganporia et al. (2014) developed a discrete-time model with arolling time horizon for the capacity planning across multiple biopharmaceutical facilities,and Shaik et al. (2014) proposed two model formulations based on discrete andcontinuous-time representations for the scheduling operation of biotech batch plants.Despite the increasing interest within the topics of biopharma, the development ofmodelling solutions for planning and scheduling problems remains a challenge, as well asexploring the wide intricacy of the operational aspects of these processes. The complexityof planning/scheduling problems in the pharmaceutical sector have been subject tosignificant attention towards the use of optimisation models and techniques (Shah, 2004).The novelty of these bioprocesses have placed new challenges in modelling research,either addressing the strict process regulatory constraints, products storage shelf-lifelimitations and biological variability, or campaign basis to comply with product qualityrequirements and minimise cross-product contamination. Simaria et al. (2012) identifiedthat biopharmaceutical facilities will tend to adopt a smaller scale with multiplebioreactors, able to reduce the capital cost and optimising the number of productionbatches to match uncertain demand. Traditional batch processing may still remain thepredominant approach to manufacturing (Ramasamy et al., 2014), but technologicalenhancements in continuous processes (e.g. perfusion technique) are showing improvedproductivities and operational outcomes. Likewise, to comply with process licensure, theoption to use typical stainless steel vessels, with required cleaning in-between batches,can be evaluated against the alternative of single-use disposable equipment.Noteworthy, the general problem of planning and scheduling operations has beengathering extensive research in process industry, with relevance to modelling andoptimisation scheduling methodologies as reviewed by Mendez et al. (2006) andHarjunkoski et al. (2014). The approaches based on a unified process representation, boththe State-Task Network (STN) and the Resource-Task Network (RTN) proposed by Kondiliet al. (1993) and Pantelides (1994) respectively, have proven to be effective in mostclasses of scheduling problems. As an example of a real pharmaceutical industrialscheduling problem, Moniz et al. (2013) proposed an MILP discrete time formulationbased on the RTN framework, considering some production constraints, such as sequence-dependent changeovers, temporary storage in processing units, lots blending/splittingand materials traceability.The boundaries of planning/scheduling problems are typically associated with the type ofdecision detail required for a given time-horizon, ranging from several hours/days (short-term scheduling) to several weeks/months (campaign scheduling/mid-term planning).Regarding the time-horizon model representation, two different approaches have beenexplored: discrete-time and continuous-time. The discrete-time formulations considersthe division of the time horizon into equal length intervals, assuming fixed processingtimes multiple of those intervals, see for instance the recent work by Moniz et al. (2014a),while the continuous-time formulations can be more sensitive to changes in the tasksduration, for example to deal with continuous processes, where the start/duration of thescheduled slots in the time horizon remains a variable. The continuous-time formulationscan rely on a single time-grid common to all resources (Maravelias and Grossmann (2003)and Castro (2010)) or multiple time-grids for each resource of the process (Shaik andFloudas (2008) and Shaik and Floudas (2009)). However, it is acknowledged that eachmodel approach is strongly determined by the selected problem representation of thematerial flow and unit specific constraints, which impacts on its complexity andperformance.
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Considering the characteristics of the planning and campaign scheduling problems in abiopharmaceutical facility, the proposed MILP model is based on the RTN frameworkusing a continuous-time formulation with a single time-grid. The mathematicalformulation aims at addressing the main planning/scheduling constrains of thesebioprocesses, namely, the schedule of batch and/or continuous process steps, multipleintermediate deliveries, sequence dependent cleaning operations, storage of productsregarding shelf-life limitations, and the track-control of the production lots for regulatorypolicies.3 MODEL CHARACTERISTICS
3.1 Problem definitionThis study proposes the development of a continuous-time MILP model, based on the RTNframework, to address the optimal planning of the production and determine for eachcampaign the schedule with unitΫǡϐȀmaterial through the plant of a biopharmaceutical process. The objective is to maximisethe profit by determining the optimal task-unit assignment and sequencing, sequencedependent changeovers, the temporary storage allocation, campaign-lots number andduration/size and eventual blending/splitting requirements, given:(i) the product recipes in terms of their respective RTN framework;(ii) the product demands and due dates;(iii) the characteristics of the processing units;(iv) processing times, operational costs and the task-unit suitability;(v) the shelf-life storage of intermediaries/products;(vi) the value of the products;(vii) and the costs for all materials.
3.2 Mathematical FormulationThe problem defined above is modelled through a RTN continuous-time formulation basedon the model proposed by Castro et al. (2004), which accesses our premise to addressboth batch and continuous processes. It must be noted that, by process definition, in abatch operation mode the materials are entirely consumed at the start of the respectiveproduction task, and the amount produced is made available only at its finish. However, ina continuous operation, a production flow rate is verified along the duration of the task,which allows that sequential continuous tasks can occur simultaneously. The identifiedfeatures of planning and campaign scheduling problems in biopharmaceutical processesare addressed by extending the baseline formulation with a new set of variables andconstraints detailed as follows. The mathematical nomenclature can be found at the end ofthis article.
3.2.1 Resource Task Network frameworkThe RTN process framework unifies the model formulation in terms of two sets ofentities: tasks and resources. A task is an operation that transforms a set ofresources, which includes all entities involved in the process such as materials orprocessing units. The tasks can interact with resources discretely at its start andfinish (batch tasks), and/or continuously at a rate that remains constantthroughout its duration (continuous tasks). The initial formulation proposed byPantelides (1994) considered a discrete-time formulation, dividing the timehorizon H into fixed and uniform time intervals. Instead, in a continuous-time
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formulation the length of each interval is unknown, being more sensitive to smallchanges in task durations (Schilling and Pantelides, 1996). The continuous-timeformulation presented in this paper considers a common time grid to all resourcesand events taking place in the planning horizon. As shown in Figure 1, the timehorizon H is divided into a given number of slots (T-1), but contrary to its discrete-time formulation, the absolute time of the event point t is determined throughvariable Tt.
Figure 1 – Single time grid for the continuous-time modelThe RTN continuous-time formulation, as well as its discrete-time counterpart,considers binary N and continuous ߦ variables to characterise the event of task istarting at point t and ending at (or before) point t’>t (Castro et al., 2004).Moreover, to assure typical regulatory policies of the pharmaceutical processes(Moniz et al., 2013), these variables are now extended to include a lot index l,congregate 4-indeces݈݅ ݐݐ′. The binary variable ܰ௜௟௧௧ᇱ is equal to one if lot l of task istarts at event point t and finish until event point t’, ߦ௜,௟,௧,௧ᇲ gives the lot amount ofmaterial processed within the same time slot [t,t’]. This modelling featureenhances the ability to trace the schedule of different lots of the same productcampaign that, for example, could be blended/splitted during the process. Theextent variable of the task for a certain time interval defines the total campaign-lotamount to be produced, suitable to address the size/duration of the campaignaccording to the requirements of the production plan.The biopharmaceutical processes can consider either batch and/or continuoustasks throughout its production steps, according to the selection of technologicalequipment. The amount of each resource produced or consumed is assumed to beproportional to the characteristic variables of the task by a set of structuralparameters. The parameters ߤ௜,௥௣ andߤ௜,௥௖ associate the discrete interactions withthe ܰ௜,௟,௧,௧ᇲ variables, used whenever the amount of resource r produced orconsumed is independent of the amount processed, as it is the case of equipmentitems. For material resources, discrete iterations parameters ݒ௜,௥௣ and ݒ௜,௥௖ links theextent variablesߦ௜,௟,௧,௧ᇲ to the amount processed. A task can also interact in acontinuous manner with one or more resources for its duration (typically materialresources), where parameter ߣ௜,௥ accounts for the rate of generation of theresource associated with the extent variableߦ௜,௟,௧,௧ᇲ. As example, Figure 2 shows ageneral RTN representation for a process composed by two consecutive tasks. Thebatch task (TB) consumes material A and produces material B, while thecontinuous task (TC) consumes material B and produces material C. Moreover,task TB requires the processing unit U and task TC the processing unit M. Thedashed lines represent discrete interactions, while solid lines depict continuousinteractions (noted that interactions with equipment are, by model definition,always discrete). In each connection the previous parameters are identified,where, for each task, negative values will grant the consumption of the respectiveresource r on task i for one interval [ݐ,ݐ’], whereas positive values denoteproduction.
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Figure 2 – RTN process representation
3.2.2 Timing constraintsTo account for the duration of a task i, it is assumed that the processing time can begiven by a constant ߙ௜plus a term proportional ߚ௜to the amount of material beingprocessed, asሺߙ௜൅ ߚ௜ߦ௜ǡ௟ǡ௧ǡ௧ᇲ). This allows to represent all types of tasks, forexample, either a batch task Ib with a fixed duration (e.g. ߙ௜>0 and ߚ௜= 0) or acontinuous task Ic with processing rate ߩ௜ (e.g. ߙ௜=0 and ߚ௜=1/ߩ௜ ) withߩ௜ ∈
ൣߩ௜
௠ ௜௡ǡߩ௜
௠ ௔௫൧. With the assumption that only one task per lot can be executed at anyprocessing equipment (ݎא ̳ܧ ܧݏݐ) at each time interval, equation 1 imposes thatthe difference between the absolute times of two event points ሾݐǡݐǯሿ൐ Ͳ must beeither greater or equal than the processing time of the tasks starting and finishingwithin the interval. Thereby, the first term is referred to the sum of batch tasks andthe second to continuous tasks. Since this formulation allows the relaxation of theduration of the tasks in each time interval, equation 2 assures that, if required,time constraints are satisfied for batch tasks subject to zero-wait policies (Izw) orfor continuous tasks that must exceed a certain minimum rate (Imr).
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௣
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∀ݎ∈ ܧ\ܧ௦௧,ݐ∈ ,ܶݐᇱ∈ ,ܶݐ< ݐᇱ,ݐ≠ | |ܶ
(2)
To withhold the combinatorial extent of variables and constraints, it is reasonableto introduce in the formulation a parameter οݐൌ ሺݐᇱെ ݐሻto define the maximumnumber of consecutive events points allowed for each task to occur. The use of afixed value for οݐis quite reasonable in cases where it is expected that few eventpoints exist between the beginning and end of a task, but this parameter should beevaluated for each problem to not compromise the model feasibility or reachsuboptimal solutions. To simplify the model formulation, we will consider a single
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∆ݐparameter only applied to batch tasks, assuming, without loss of generality, thatany instance of tasks performed in a continuous mode can last for only one timeinterval (∆ݐ= 1). Since in each time interval only one task can take place in eachequipment resource, the previous general time equations 1 and 2 can be rewrittento consider this ∆ݐ approach for either batch tasks (equations 3 and 4) andcontinuous tasks (equations 5 and 6). Moreover, each equation considers theadditional time related to task changeover procedures (δ௜,௜ᇲ), to occur within thetime interval when changeover/set-up is required to take place in thecorresponding unit (ܥ௜,௜ᇲ,௧ᇲ = 1).
ܶ௧ᇲ− ௧ܶ≥ ෍ ߤ௜௥
௣
ቌ෍ (ߙ௜ܰ ௜,௟,௧,௧ᇲ + ߚ௜ߦ௜,௟,௧,௧ᇲ)
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ቍ
௜∈ூ್
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(3)
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(4)
ܶ௧ᇲ− ௧ܶ≥ ෍ ߤ௜,௥௣ ቌ෍ ߦ௜,௟,௧,௧ᇲߩ௜௠ ௔௫௟∈௅೔ + ෍ ߜ௜,௜ᇲܥ௜,௜ᇲ,௧ᇲ௜ᇲ∈ூ೎ ቍ௜∈ூ೎
∀ݎ∈ ܧ\ܧ௦௧,ݐ∈ ,ܶݐᇱ∈ ,ܶݐ< ݐᇱ≤ ݐ+ 1,ݐ≠ |ܶ|
(5)
ܶ௧ᇲ− ௧ܶ≤ ܪ ቌ1 − ෍ ෍ ߤ௜,௥௣ ܰ௜,௟,௧,௧ᇲ
௟∈௅೔௜∈ூ೘ ೝ
ቍ
+ ෍ ߤ௜,௥௣ ቌ෍ ߦ௜,௟,௧,௧ᇲߩ௜௠ ௜௡௟∈௅೔ + ෍ ߜ௜,௜ᇲܥ௜,௜ᇲ,௧ᇲ௜ᇲ∈ூ೘ ೝ ቍ௜∈ூ೘ ೝ
∀ݎ∈ ܧ\ܧ௦௧,ݐ∈ ,ܶݐᇱ∈ ,ܶݐ< ݐᇱ≤ ݐ+ 1,ݐ≠ |ܶ|
(6)
Furthermore, it is considered that during the planning horizon a set of multipledemand points ݀ ∈ ܦ must be satisfied. A similar approach has been followed byMaravelias and Grossmann (2003). The binary variable ௧ܻ,ௗ is defined to identifywhether a specific event point t corresponds to a demand points d. Here, it isassumed that each event point t, ݐ≠ 1, has to be associated with one due date d(equation 7). When those events matches, the absolute time ௧ܶ must be equal tothe specified due time ℎௗ, which is assured by equations 8 and 9.
෍ ௧ܻ,ௗ
௧∈்
௧ஷଵ
= 1 ∀ ݀ ∈ ܦ (7)
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௧ܶ≥ ෍ ℎௗ ௧ܻ,ௗ
ௗ∈஽
∀ݐ∈ ,ܶݐ≠ 1 (8)
௧ܶ≤ ෍ ℎௗ ௧ܻ,ௗ
ௗ∈஽
+ ܪ ൭1 − ෍ ௧ܻ,ௗ
ௗ∈஽
൱ ∀ݐ∈ ,ܶݐ≠ 1 (9)
Finally, equation 10 assures that no time events have the same absolute value andthese timing variables are bounded by equations 11a and 11b, considering thetime horizon interval given by [0,ܪ].
௧ܶାଵ− ௧ܶ ≥ 1 ∀ݐ∈ ,ܶݐ≠ |ܶ| (10)
ଵܶ = 0 (11a)
|்ܶ| ≤ ܪ (11b)
3.2.3 Resource balance constraintsThe resource balance equation states that the excess amount at a specific eventpoint t is equal to the amount at the previous event point. For t=1, this value refersto the initial availabilityܴ ௥,௟଴ , adjusted by the amounts discretely or continuouslyconsumed/produced by all tasks starting or ending a time event t. Constraints formaterials resources (set M) of lot l (equations 12-15) are modelled separately fromequipment units (set E) (equation 16).Equation 12 stresses the general balance for all material resourcesݎ∈ ܯ , where
ܴ௥,௟,௧ characterises the excess resource r availability of lot l and time point t. Inaddition to the initial or previous term of the balance, ܴ௥,௟,௧௣ and ܴ௥,௟,௧௖ represents theamount produced and consumed, respectively. The variable ܹ ௥,௟,௧ is related to thewaste disposal amount when resource shelf-life is exceeded and Π௥,௟,௧ to theamount expedited at a corresponding due date. The variables ܴ௥,௟,௧௖ and Π௥,௟,௧ areconsidered negative in the balance.The amount of material produced is formulated through equation 13, where thefirst term is related to batch tasks and the second to continuous tasks that produceresource r of lot݈∈ ܮ௥. Likewise, equations 14 and 15 formulate the materialconsumption. However, the latter equation extends the feature of blending lots ofstable intermediaries or products to originate other lots of intermediaries or finalproducts (Moniz et al., 2014a). It addresses the consumption balance for a set ܮ஻௥of lots of resourceݎ∈ ܤthat are able to be blended, allowing the tracking of theblending process.
ܴ௥,௟,௧ = ܴ௥,௟଴ |௧ୀଵ + ܴ௥,௟,௧ି ଵ|௧வଵ + ܴ௥,௟,௧௣ + ܴ௥,௟,௧௖ − ܹ ௥,௟,௧+ Π௥,௟,௧
∀ݎ∈ ܯ ,݈∈ ܮ௥,ݐ∈ ܶ (12)
ܴ௥,௟,௧௣ = ෍ ෍ ݒ௜,௥௣ ߦ௜,௟,௧ᇲ,௧
௧ᇲ∈ܶ
௧ି ∆ݐஸ௧ᇲழ௧
௜∈ூ್
+ ෍ ෍ ߣ௜,௥ߦ௜,௟,௧ᇲ,௧
௧ᇲ∈ܶ
௧ି ଵஸ௧ᇲழ௧
௜∈ூ೎
∀ݎ∈ ܯ ,݈∈ ܮ௥,ݐ∈ ܶ (13)
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ܴ௥,௟,௧௖ = ෍ ෍ ݒ௜,௥௖ ߦ௜,௟,௧,௧ᇲ
௧ᇲ∈ܶ
௧ழ௧ᇲஸ௧ା∆ݐ
௜∈ூ್
+ ෍ ෍ ߣ௜,௥ߦ௜,௟,௧ᇲ,௧
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௧ି ଵஸ௧ᇲழ௧
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௧ᇲ∈ܶ
௧ழ௧ᇲஸ௧ାଵ
௜∈ூೝಳ಴
೎
∀ݎ∈ ܯ \ܤ,݈∈ ܮ௥,ݐ∈ ܶ
(14)
෍ ܴ௥,௟,௧௖
௟∈௅ಳ
ೝ
= ෍
⎝
⎛෍ ෍ ݒ௜,௥௖ ߦ௜,௟,௧,௧ᇲ
௧ᇲ∈ܶ
௧ழ௧ᇲஸ௧ା∆ݐ
௜∈ூ್
+ ෍ ෍ ߣ௜,௥ߦ௜,௟,௧ᇲ,௧
௧ᇲ∈ܶ
௧ି ଵஸ௧ᇲழ௧
௜∈ூ೎ \ூೝಳ಴೎௟∈௅ಳೝ
+ ෍ ෍ ߣ௜,௥ߦ௜,௟,௧,௧ᇲ
௧ᇲ∈ܶ
௧ழ௧ᇲஸ௧ାଵ
௜∈ூೝಳ಴
೎
⎠
⎞
∀ݎ∈ ܤ,ݐ∈ ܶ
(15)
As previously mentioned, it is considered that only consecutive continuous taskscan occur simultaneously in the same time schedule [ݐ,ݐ’] (in different equipmentunits) and the formulation should restrict the schedule of any other combinations.Albeit, the tests performed to the baseline formulation by Castro et al. (2004)verifies all tasks combinations except one: an additional term is required to assurethat when a continuous task consumes the intermediate material r produced by abatch task (subsetܫ௥஻஼௖ ), that occurs in different time intervals, which is guaranteedby the last term of equations 14 and 15. To further explain this feature, in Figure 3is schematised a generic production process of product D composed by a set ofthree tasks: the first as a batch task TB (1 × ܣ → 1 × ܤ) followed by twocontinuous steps, TC1 (1 × ܤ → 1 × ܥ) and TC2 (1 × ܥ → 0.5 × ܦ). Forsimplification, lets consider the main balance equations for material resources(Equation 12-14), assuming that all tasks can last only a single time interval (∆ݐ=1) and disregarding all aspects related to the lot features. Considering twodemand dates for product D (50kg @21 hours and 60kg @33 hours), the Ganttchart shows the sequence of scheduled tasks to fulfil that deliveries (Π஽ ,௟,ଷ , Π஽ ,௟,ସ).But as can be noticed, to accurately calculate the balance for intermediatematerials B and C, it cannot be based on the same “consumption” term of theequation, as the original formulation suggests. With this reformulation isguaranteed, through the term applied to the set of tasks ܫ௥஻஼௖ , that if material B isproduced (at TB) in interval [ݐ− 1,ݐ], it is only consumed (at TC1) in the followinginterval [ݐ,ݐ+ 1]. In the case of material C, since it is used by two consecutivecontinuous tasks, its production and consumption can occur on the same timeinterval [ݐ− 1,ݐ].
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Figure 3 – Representation of process modelling formulation (material resource balance)The resource balance constraints to equipment resources E is presented inequation 16. Here, the index l in the balance variable ܴ௥,௧ is dropped since the lottraceability is only required for material resources. The initial terms of equation 16follow the same resource availability concerning the occurrence of batch and/orcontinuous tasks that take place in the boundaries of the time event. The last termrefers to the set of storage tasks of each material resource/lot (݅∈ ܫ௦௧). Thisequation assumes that all equipment resources are considered individually, withexception of storage tanks (ݎ∈ ܧ௦௧) which are considered a group of entitiesavailable (ܴ௥௜௡௜௧ > 1), assigned for each product storage when required.
ܴ௥,௧ = ܴ௥଴|(௧ୀଵ) + ܴ௥,௧ି ଵ|௧வଵ
+ ෍ ෍
⎝
⎛ ෍ ൫ߤ௜,௥௣ ܰ௜,௟,௧ᇲ,௧൯
௧ᇲ∈்
௧ି ∆௧ஸ௧ᇲழ௧
+ ෍ ൫ߤ௜,௥௖ ܰ௜,௟,௧,௧ᇲ൯
௧ᇲ∈்
௧ழ௧ᇲஸ௧ା∆௧ ⎠
⎞
௟∈௅ೝ௜∈ூ್
+ ෍ ෍
⎝
⎛ ෍ ൫ߤ௜,௥௣ ܰ௜,௟,௧ᇲ,௧൯
௧ᇲ∈்
௧ି ଵஸ௧ᇲழ௧
+ ෍ ൫ߤ௜,௥௖ ܰ௜,௟,௧,௧ᇲ൯
௧ᇲ∈்
௧ழ௧ᇲஸ௧ାଵ ⎠
⎞
௟∈௅ೝ௜∈ூ೎+ ෍ ෍ ൫ߤ௜,௥௣ ܰ௜,௟,௧ି ଵ,௧+ ߤ௜,௥௖ ܰ௜,௟,௧,௧ାଵ൯
௟∈௅ೝ௜∈ூೞ೟
∀ݎ∈ ܧ,ݐ∈ ܶ
(16)
Equation 17 performs the initial assignment of the equipment units E, consideringprocessing and storage units, and equation 18 bounds the allowed resourceavailabilities. Equation 19 guarantees that, when applied, no material resourceother than the raw materials (RM) is allowed be stored at the last event of the timehorizon. This restriction is particularly useful to access the case that products/by-products cannot be stored beyond the planning horizon due to shelf-life restrains.
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ܴ௥
଴ ≤ ܴ௥
௜௡௜௧ ∀ ݎ∈ ܧ (17)0 ≤ ෍ ܴ௥,௟,௧
௟∈௅ೝ
≤ ܴ௥
௠ ௔௫ ∀ ݎ∈ ܯ ,ݐ∈ ܪ (18)
෍ ෍ ܴ௥,௟,௧
௟∈௅ೝ௥∈ெ \ோெ = 0 ∀ ݐ= | |ܶ (19)
3.2.4 Lot constraintsAccording to Moniz et al. (2013), a distinction must be made in the formulation oflots and task–batches. Lots characterise the amount of stable intermediate or finalproduct produced throughout a known set of tasks executed in a knownproduction sequence or recipe. Task-batches are related to the amount of materialproduced by each task that is limited by the capacity of the processing unit,executing part of the production of a lot. In this way, the formulation addresses theability to trace the proportions/quantities of all products lots in the productionschedule, allowing the record of the processing of a certain lot (or a lot blend/split,if allowed) through the task-batching of raw materials, intermediate and finalproducts.Regarding the lot traceability of the produced materials, two additional constrainsare considered to enhance the model features. Equations 20 and 21 states that, foreither batch or continuous tasks, respectively, lot l is only executed if the lot l−1was already assigned, in a previous time interval, to a task that can produce thesame material resource (first subtracting term), or up to the same interval but inan alternative equipment unit (second subtracting term). Equation 22 allows that,if required, lot l of a material resource is never repeated during the planninghorizon, which, when no limits are set to a predefined number of lots, allows thedetermination of the total number of lots required.
ݒ௜,௥௣ ܰ௜,௟,௧,௧ᇲ− ෍ ෍ ݒ௜,௥௣ ܰ௜,௟ି ଵ,௧ᇲᇲᇲ,௧ᇲᇲ
௧ᇲᇲᇲ∈்
௧ᇲᇲି ∆௧ஸ௧ᇲᇲᇲழ௧ᇲᇲ
௧ᇲᇲ∈்
௧ᇲᇲஸ௧
− ෍ ෍ ෍ ݒ௜,௥௣ ܰ௜ᇲ,௟ି ଵ,௧ᇲᇲᇲ,௧ᇲᇲ
௧ᇲᇲᇲ∈்
௧ᇲᇲି ∆௧ஸ௧ᇲᇲᇲழ௧ᇲᇲ
௧ᇲᇲ∈்
௧ᇲᇲஸ௧ᇲ
௜ᇲ∈ூ್
௜ᇲஷ௜
≤ 0
∀ݎ∈ ܯ \ܴܯ ,݅∈ ܫ௕,݈∈ ܮ௥,݈> 1,ݐ∈ ,ܶݐᇱ∈ ,ܶݐ< ݐᇱ≤ ݐ+ ∆ݐ,ݐ≠ |ܶ|
(20)
ߣ௜,௥ܰ௜,௟,௧,௧ᇲ− ෍ ෍ ߣ௜,௥ܰ௜,௟ି ଵ,௧ᇲᇲᇲ,௧ᇲᇲ
௧ᇲᇲᇲ∈்
௧ᇲᇲି ଵஸ௧ᇲᇲᇲழ௧ᇲᇲ
௧ᇲᇲ∈்
௧ᇲᇲஸ௧
− ෍ ෍ ෍ ߣ௜,௥ܰ௜ᇲ,௟ି ଵ,௧ᇲᇲᇲ,௧ᇲᇲ
௧ᇲᇲᇲ∈்
௧ᇲᇲି ଵஸ௧ᇲᇲᇲழ௧ᇲᇲ
௧ᇲᇲ∈்
௧ᇲᇲஸ௧ᇲ
௜ᇲ∈ூ೎
௜ᇲஷ௜
≤ 0
∀ݎ∈ ܯ \ܴܯ ,݅∈ ܫ௖,݈∈ ܮ௥,݈> 1,ݐ∈ ,ܶݐᇱ∈ ,ܶݐ< ݐᇱ≤ ݐ+ 1,ݐ≠ |ܶ|
(21)
෍ ෍ ෍ ݒ௜,௥௣
௧ᇲᇲ∈்
௧ழ௧ᇲஸ௧ା∆௧
ܰ௜,௟,௧,௧ᇲ
௧∈்
௧ஷ|்|௜∈ூ್ + ෍ ෍ ෍ ߣ௜ᇲ,௥௧ᇲ∈்௧ழ௧ᇲஸ௧ାଵ ܰ௜ᇲ,௟,௧,௧ᇲ௧∈்௧ஷ|்|௜∈ூ೎ ≤ 1
∀ݎ∈ ܯ \ܴܯ ,݈∈ ܮ௥ (22)
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3.2.5 Multiple deliveries constraintsThe multiple deliveries feature is modelled through equations 23 to 25. Equation23a defines the multiple product/lot deliveries trough variable Π௥,௟,௧, with a set ofdue dates d ϵ D and products P. The amount of resource r of one lot l at due date dcan be bounded by minimum ܳ௥,௟,ௗ௠ ௜௡ and maximum quantitiesܳ ௥,௟,ௗ௠ ௔௫, while in eachdue date the unfulfilled minimum demand of product r of lot l is given by Π௥,௟,௧௨ .Considering that, in our approach, the total number of lots l to schedule can bedefined as an output solution, equation 23b accesses the same balance assuming aminimum demand profile for single product (combining all lots) per due date, ܳ௥,ௗ.The formulation also allows that a delivery could occur in any time event of theplanning horizon, besides the predefined due dates. Therefore, equation 24guarantees that no early deliveries are allowed, as well as that the total demand ofeach product P is not exceeded. Finally, equation 25 assures that no deliveries existfor other resources than products P.
෍ ( ௧ܻ,ௗ
ௗ∈஽ೝ
Q௥,௟,ௗ௠ ௜௡ ) − Π௥,௟,௧௨ ≤ (−Π௥,௟,௧) ≤ ෍ ( ௧ܻ,ௗ
ௗ∈஽ೝ
Q௥,௟,ௗ௠ ௔௫)
∀ ݎ∈ ܲ,݈∈ ܮ௥,ݐ∈ ,ܶݐ> 1 (23a)
෍ ( ௧ܻ,ௗ
ௗ∈஽ೝ
Q௥,ௗ) − ෍ Π௥,௟,௧௨
௟∈௅ೝ
≤ ෍ (−Π௥,௟,௧
௟∈௅ೝ
)
∀ ݎ∈ ܲ,ݐ∈ ,ܶݐ> 1 (23b)
෍ (−Π௥,௟,௧)
௟∈௅ೝ
≤ ෍ ෍ (ܻ௧ᇲ,ௗ
ௗ∈஽ೝ
Q௥,ௗ)
௧ᇲ∈்
௧ᇲஸ௧
− ෍ ෍ ൫−Π௥,௟,௧ᇲ൯
௟∈௅ೝ௧ᇲ∈்
௧ᇲழ௧
∀ ݎ∈ ܲ,ݐ∈ ,ܶݐ> 1 (24)
Π௥,௟,௧ = 0 ∀ ݎ∈ ܯ /ܲ,݈∈ ܮ௥,ݐ∈ ܶ (25)
3.2.6 Operational constraintsAssuming that each task can be performed in a single processing unit, equation 26accounts for equipment capacity restrains of batch tasks ( ௜ܸ,௟௠ ௜௡andܸ௜,௟௠ ௔௫). Forcontinuous tasks, the boundaries are related to the processing rate and length ofthe interval (equation 27). In this case, the lower limit is defined by the minimumcampaign length of the processing task i, set by parameterܥܽ݉ ݌௜,௟, and the upperlimit to the lifetime of the processed products at the same tasksߪ௜,௟. This last termreinforces that the product shelf life will never be exceeded during one singlecontinuous task. If required, the same principle can be followed for a batch task byassuming a maximum capacity of the equipment suitable to comply with lifetime ofprocessed materials.
௜ܸ,௟௠ ௜௡ܰ௜,௟,௧,௧ᇲ≤ ߦ௜,௟,௧,௧ᇲ≤ ௜ܸ,௟௠ ௔௫ܰ௜,௟,௧,௧ᇲ
∀ ݅∈ ܫ௕,݈∈ ܮ௜,ݐ∈ ,ܶݐᇱ∈ ,ܶݐ< ݐᇱ< ݐ+ ∆ݐ,ݐ≠ | |ܶ (26)
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ܥܽ݉ ݌௜,௟ߩ௜௠ ௔௫ܰ௜,௟,௧,௧ᇲ≤ ߦ௜,௟,௧,௧ᇲ≤ ߪ௜,௟ߩ௜௠ ௔௫ܰ௜,௟,௧,௧ᇲ
∀ ݅∈ ܫ௖,݈∈ ܮ௜,ݐ∈ ,ܶݐᇱ∈ ,ܶݐ< ݐᇱ< ݐ+ 1,ݐ≠ | |ܶ (27)
3.2.7 Sequence dependent changeover constraintsThe production schedule should also address the required cleaning proceduresbased on sequence dependent changeovers, considered in our formulation as anautonomous task. In biopharmaceutical processes the changeover task can usuallyinclude, besides the cleaning time, any setup time related to process start-up of thefollowing production. For example, considering two consecutive tasks { ,݅݅ᇱ} ofintermediaries products at the time event ݐ, if the task ݅ᇱ processes a differentproduct than݅, it is required an intermediate changeover of the shared processingunit (ݎ∈ ܧ\ܧ௦௧) to occur before the beginning of task݅ᇱ with a specifieddurationߜ௜,௜ᇲ. To avoid the increase in the number of scheduled time events, thistask is implicitly allocated to the duration of one time interval in the boundary of ݐwhere the changeover is required. The novelty presented relies in the flexibility ofthe allocation to the previous time interval, assuming its performed immediatelybefore ݐ, or starting at the beginning of the following interval. As example, Figure 4shows the two schedule possibilities for a general case of two products, A and B,able to be produced in the same unit, allowing the increase of the productionoutput of B depending in the allocation of the required changeover task. Thisflexibility potentiates the objective function results and is particular relevant insingle-time grid horizon formulations. Therefore, in equations 28 and 29, a binaryvariable ܥ௜,௜ᇲ,௧ is introduced to control the sequence of tasks ݅≠ ݅ᇱand allocation ofthe require intermediate changeover in the shared equipment, respectively foreither batch or continuous task. The same variable is also required to associate acost to these operations, further penalised in the objective function. However, thiscase is only verified for consecutive tasks in a time event, which implies toconsider whenever empty time intervals exist in between two events (ݐᇱ> ݐ),adding a new term to equations 30 and 31 to access the changeover time in theboundaries of ݐ’. Likewise, equations 32 and 33 address the set-up requirementsfor the first scheduled task on each equipment with the binary variable ܥ௜,௜,௧. Toavoid suboptimal solutions, equation 34 reinforces that in each time interval onlyone cleaning task takes place per equipment resource.
Figure 4 –Changeover tasks allocation options for a production case [A+B]
෍ ෍ ߤ௜,௥௣ ܰ௜,௟,௧ᇲ,௧
௧ᇲ∈்
௧ି ∆௧ஸ௧ᇲழ௧
௟∈௅೔
+ ෍ ෍ ߤ
௜ᇲ,௥௣ ܰ௜ᇲ,௟,௧,௧ᇲ
௧ᇲ∈்
௧ழ௧ᇲஸ௧ା∆௧
௟∈௅೔ᇲ
≤ 1 + ߤ௜,௥௣ ܥ௜,௜ᇲ,௧+ ߤ௜,௥௣ ܥ௜,௜ᇲ,௧ାଵ
∀ݎ∈ ܧ\ܧ௦௧,݅∈ ܫ௕ ,݅ᇱ∈ ܫ௕ ,݅ᇱ≠ ,݅ݐ∈ ,ܶݐ> 1,ݐ≠ |ܶ|
(28)
2 batches of A (40 days)CO/Setup A10 days CO/Setup B10 days 5 batches of B (50 days)
2 batches of A (40 days)CO/Setup A10 days CO/Setup B10 days 6 batches of B (60 days)380 days 4140 days
OPTION2
OPTION1
t= 1
1 batch of A(20 days)
1 batch of A(20 days)250 days
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෍ ෍ ߤ௜,௥௣ ܰ௜,௟,௧ᇲ,௧
௧ᇲ∈்
௧ି ଵஸ௧ᇲழ௧
௟∈௅೔
+ ෍ ෍ ߤ
௜ᇲ,௥௣ ܰ௜ᇲ,௟,௧,௧ᇲ
௧ᇲ∈்
௧ழ௧ᇲஸ௧ାଵ
௟∈௅೔ᇲ
≤ 1 + ߤ௜,௥௣ ܥ௜,௜ᇲ,௧+ ߤ௜,௥௣ ܥ௜,௜ᇲ,௧ାଵ
∀ݎ∈ ܧ\ܧ௦௧,݅∈ ܫ௖ ,݅ᇱ∈ ܫ௖ ,݅ᇱ≠ ,݅ݐ∈ ,ܶݐ> 1,ݐ≠ |ܶ| (29)
෍ ෍ ߤ௜,௥௣ ܰ௜,௟,௧ᇲᇲ,௧
௧ᇲᇲ∈்
௧ି ∆௧ஸ௧ᇲᇲழ௧
௟∈௅೔
+ ෍ ෍ ߤ
௜ᇲ,௥௣ ܰ௜ᇲ,௟,௧ᇲ,௧ᇲᇲ
௧ᇲᇲ∈்
௧ᇲழ௧ᇲᇲஸ௧ᇲା∆௧
௟∈௅೔ᇲ
− ෍ ෍ ෍ ෍ ߤ
௜ᇲᇲ,௥௣ ܰ௜ᇲᇲ,௟,௧ᇲᇲ,௧ᇲᇲᇲ
௧ᇲᇲᇲ∈்
௧ᇲᇲழ௧ᇲᇲᇲஸ௧ᇲᇲା∆௧
௧ᇲᇲ∈்
௧ஸ௧ᇲᇲழ௧ᇲ
௟∈௅೔ᇲᇲ௜ᇲᇲ∈ூ್
≤ 1 + ߤ௜,௥௣ ܥ௜,௜ᇲ,௧ᇲ + ߤ௜,௥௣ ܥ௜,௜ᇲ,௧ᇲାଵ
∀ݎ∈ ܧ\ܧ௦௧,݅∈ ܫ௕ ,݅ᇱ∈ ܫ௕ ,݅ᇱ≠ ,݅ݐ∈ ,ܶݐᇱ∈ ,ܶݐ> 1,ݐᇱ> ݐ,ݐ≠ |ܶ|,ݐᇱ
≠ |ܶ|
(30)
෍ ෍ ߤ௜,௥௣ ܰ௜,௟,௧ᇲᇲ,௧
௧ᇲᇲ∈்
௧ି ଵஸ௧ᇲᇲழ௧
௟∈௅೔
+ ෍ ෍ ߤ
௜ᇲ,௥௣ ܰ௜ᇲ,௟,௧ᇲ,௧ᇲᇲ
௧ᇲᇲ∈்
௧ᇲழ௧ᇲᇲஸ௧ᇲାଵ
௟∈௅೔ᇲ
− ෍ ෍ ෍ ෍ ߤ
௜ᇲᇲ,௥௣ ܰ௜ᇲᇲ,௟,௧ᇲᇲ,௧ᇲᇲᇲ
௧ᇲᇲᇲ∈்
௧ᇲᇲழ௧ᇲᇲᇲஸ௧ᇲᇲାଵ
௧ᇲᇲ∈்
௧ஸ௧ᇲᇲழ௧ᇲ
௟∈௅೔ᇲᇲ௜ᇲᇲ∈ூ೎
≤ 1 + +ߤ௜,௥௣ ܥ௜,௜ᇲ,௧ᇲ + ߤ௜,௥௣ ܥ௜,௜ᇲ,௧ᇲାଵ
∀ݎ∈ ܧ\ܧ௦௧,݅∈ ܫ௖ ,݅ᇱ∈ ܫ௖ ,݅ᇱ≠ ,݅ݐ∈ ,ܶݐᇱ∈ ,ܶݐ> 1,ݐᇱ> ݐ,ݐ≠ |ܶ|,ݐᇱ
≠ |ܶ|
(31)
෍ ෍ ߤ௜,௥௣ ܰ௜,௟,௧,௧ᇲ
௧ᇲ∈்
௧ழ௧ᇲஸ௧ା∆௧
௟∈௅೔
− ෍ ෍ ෍ ෍ ߤ
௜ᇲ,௥௣ ܰ௜ᇲ,௟,௧ᇲᇲ,௧ᇲ
௧ᇲᇲ∈்
௧ᇲି ∆௧ஸ௧ᇲᇲழ௧ᇲ
௧ᇲ∈்
௧ᇲஸ௧
௟∈௅೔ᇲ௜ᇲ∈ூ್
ተ
௧வଵ
≤ ߤ௜,௥௣ ܥ௜,௜,௧ାଵ + ߤ௜,௥௣ ܥ௜,௜,௧ห௧வଵ
∀ݎ∈ ܧ\ܧ௦௧,݅∈ ܫ௕ ,ݐ∈ ,ܶݐ≠ |ܶ|
(32)
෍ ෍ ߤ௜,௥௣ ܰ௜,௟,௧,௧ᇲ
௧ᇲ∈்
௧ழ௧ᇲஸ௧ାଵ
௟∈௅೔
− ෍ ෍ ෍ ෍ ߤ
௜ᇲ,௥௣ ܰ௜ᇲ,௟,௧ᇲᇲ,௧ᇲ
௧ᇲᇲ∈்
௧ᇲି ଵஸ௧ᇲᇲழ௧ᇲ
௧ᇲ∈்
௧ᇲஸ௧
௟∈௅೔ᇲ௜ᇲ∈ூ೎
ተ
௧வଵ
≤ ߤ௜,௥௣ ܥ௜,௜,௧ାଵ + ߤ௜,௥௣ ܥ௜,௜,௧ห௧வଵ
∀ݎ∈ ܧ\ܧ௦௧,݅∈ ܫ௖ ,ݐ∈ ,ܶݐ≠ |ܶ|
(33)
෍ ෍ ߤ௜,௥௣ ܥ௜,௜ᇲ,௧
௜ᇲ∈ூ್ ∪ூ೎
௜ᇲஷ௜
௜∈ூ್ ∪ூ೎
≤ 1
∀ݎ∈ ܧ\ܧ௦௧,ݐ∈ ,ܶݐ> 1,ݐ≠ |ܶ| (34)
3.2.8 Storage and shelf-life constraintsConsidering a set of storage tasks for each intermediaries and final productsܫ௦௧ =
ܫ௦௧
஻ ∪ ܫ௦௧
஼ and a set of storage equipment resourcesݎ∈ ܧ௦௧, the model should
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constraint the stored products to shelf-life time restrains. Shelf-life must beconsidered as the maximum lifetime a product/by-product is able to be stored(ߪ௜,௟), sending to waste disposal the respective amounts when this parameter isexceed. Equations 35 to 37 control the activation of a storage task in the boundaryintervals if there is an excess amount at event point t of the material resource r oflot l. Due to the different processing mode of tasks, it is considered that formaterials produced by batch tasks, the storage task ܫ௦௧஻ must be activate only to theensuing interval [ݐ, ݐ+ 1]. Instead, the storage of materials produced bycontinuous tasks, ܫ௦௧஼ , must be activate on both intervals, [ݐ− 1 ,ݐ] and [ݐ, ݐ+ 1],since it is assumed that the material is processed continuously from the start of theinterval. Additionally, in the case of intermediaries consumed by continuous tasks,the storage task ܫ௦௧ூே்_஼ task must be active on [ݐ+ 1, ݐ+ 2].
௜ܸ,௟௠ ௜௡ܰ௜,௟,௧,௧ାଵ ≤ ෍ ܴ௥,௟,௧
௥∈ூೝ
ೞ೟
≤ ௜ܸ,௟௠ ௔௫ܰ௜,௟,௧,௧ାଵ
∀ ݅∈ ܫ௦௧
஻ ∪ ܫ௦௧
஼ ,݈∈ ܮ௜,ݐ∈ ,ܶݐ≠ | |ܶ (35)
௜ܸ,௟௠ ௜௡ܰ௜,௟,௧ି ଵ,௧≤ ෍ ܴ௥,௟,௧
௥∈ூೝ
ೞ೟
≤ ௜ܸ,௟௠ ௔௫ܰ௜,௟,௧ି ଵ,௧
∀ ݅∈ ܫ௦௧
஼ ,݈∈ ܮ௜,ݐ∈ ,ܶݐ≠ 1 (36)
௜ܸ,௟௠ ௜௡ܰ௜,௟,௧ାଵ,௧ାଶ ≤ ෍ ܴ௥,௟,௧
௥∈ூೝ
ೞ೟
≤ ௜ܸ,௟௠ ௔௫ܰ௜,௟,௧ାଵ,௧ାଶ
∀ ݅∈ ܫ௦௧
ூே்_஼,݈∈ ܮ௜,ݐ∈ ,ܶݐ≠ 1 (37)
To accurately control the shelf-life of stored materials, and since each storage task(݅∈ ܫ௦௧) is activated for the entire time interval, the variable ݔ௜,௟,௧,௧ᇲ is introduced tocontrol the storage time of the corresponding material resource r of lot l. Asexample, the variable ݔ௜,௟,௧,௧ାଵ should account as storage time the value of the timeperiod [t,t+1], given by ( ௧ܶାଵ− ௧ܶ), only if the storage task is active in that interval,
ܰ௜௟௧(௧ାଵ) = 1, otherwise is zero. Therefore, since ( ௧ܶାଵ− ௧ܶ) > 0 , ∀ݐ∈ ,ܶ themaster constraint could be given by the multiplication these twovariables,ݔ௜௟௧(௧ାଵ) ≡ ܰ௜௟௧(௧ାଵ) ⋅ ( ௧ܶାଵ− ௧ܶ), however generating a nonlinearfunction. Assessing the singularity of the MILP model, equations 38 to 40formulates the linearization of this proposition for the interval [t,t’].
ݔ௜,௟,௧,௧ᇲ− ܪ ෍ ܰ௜,௟,௧ᇲᇲ,௧ᇲᇲାଵ
௧ᇲᇲ∈்
௧ஸ௧ᇲᇲழ௧ᇲ
≤ 0
∀ ݅∈ ܫ௦௧,݈∈ ܮ௜,ݐ∈ ,ܶݐᇱ∈ ,ܶݐᇱ> ݐ,ݐ≠ |ܶ| (38)
ݔ௜,௟,௧,௧ᇲ≤ (ܶ௧ᇲ− ௧ܶ)
∀ ݅∈ ܫ௦௧,݈∈ ܮ௜,ݐ∈ ,ܶݐᇱ∈ ,ܶݐᇱ> ݐ,ݐ≠ | |ܶ (39)
ݔ௜,௟,௧,௧ᇲ≥ (ܶ௧ᇲ− ௧ܶ) − ܪ
⎝
⎜
⎛(ݐᇱ− ݐ) − ෍ ܰ௜,௟,௧ᇲᇲ,௧ᇲᇲାଵ
௧ᇲᇲ∈்
௧ஸ௧ᇲᇲழ௧ᇲ ⎠
⎟
⎞
∀ ݅∈ ܫ௦௧,݈∈ ܮ௜,ݐ∈ ,ܶݐᇱ∈ ,ܶݐᇱ> ݐ,ݐ≠ | |ܶ
(40)
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If a sequence of storage tasks associated with a material resource r of lot l haveextended the product lifetime ߪ௜௟a binary variable ௜ܵ,௟,௧,௧ᇱis activated (equations 41and 42). To assure the feasibility, it is assumed that the shelf-life related to anyintermediate/product is never greater that the considered time horizon H.
ݔ௜,௟,௧,௧ᇲ− ߪ௜,௟≤ ܪ ௜ܵ,௟,௧,௧ᇲ
∀ ݅∈ ܫ௦௧,݈∈ ܮ௜,ݐ∈ ,ܶݐᇱ∈ ,ܶݐᇱ> ݐ,ݐ≠ |ܶ| (41)
ݔ௜,௟,௧,௧ᇲ− ߪ௜௟≥ ܪ( ௜ܵ,௟,௧,௧ᇲ− 1)
∀ ݅∈ ܫ௦௧,݈∈ ܮ௜,ݐ∈ ,ܶݐᇱ∈ ,ܶݐᇱ> ݐ,ݐ≠ |ܶ| (42)
Equations 39 and 40 guarantee that, for an interval [t,t’], if the stored resource r oflot l has extended the product lifetime ( ௜ܵ,௟,௧,௧ᇲ = 1), the variableܹ ௥௟௧ determinesthe respective amount sent to waste disposal (ܴ௥,௟,௧ᇲି ଵ). ௦ܸ௧௠ ௔௫is a big-M scalarrelated to the overall maximum available storage capacity. Finally, equations 43and 46 assures that variable ܹ ௥,௟,௧ take value zero for all the remaining caseswhere no shelf life restrains are applied.
ܹ ௥,௟,௧ᇲ≥ ܴ௥,௟,௧ᇲି ଵ− ௦ܸ௧௠ ௔௫ቌ1 − ෍ ௜ܵ,௟,௧,௧ᇲ
௜∈ூೝ
ೞ೟
ቍ
∀ ݎ∈ ܯ /ܴܯ ,݈∈ ܮ௥,ݐ∈ ,ܶݐ< |ܶ| − 1,ݐᇱ> ݐ+ 1 (43)
ܹ ௥,௟,௧ᇲ≤ ܴ௥,௟,௧ᇲି ଵ + ௦ܸ௧௠ ௔௫ቌ1 − ෍ ௜ܵ,௟,௧,௧ᇲ
௜∈ூೝ
ೞ೟
ቍ
∀ ݎ∈ ܯ /ܴܯ ,݈∈ ܮ௥,ݐ∈ ,ܶݐ< |ܶ| − 1,ݐᇱ> ݐ+ 1 (44)
ܹ ௥,௟,௧ᇲ≤ ௦ܸ௧௠ ௔௫ ෍ ௜ܵ,௟,௧,௧ᇲ
௜∈ூೝ
ೞ೟
∀ ݎ∈ ܯ /ܴܯ ,݈∈ ܮ௥,ݐ∈ ,ܶݐ< |ܶ| − 1,ݐᇱ> ݐ (45)
෍ ܹ ௥,௟,௧
௧∈்
= 0
∀ ݎ∉ ܯ /ܴܯ ,݈∈ ܮ௥ (46)
3.2.9 Objective functionRegarding the objective function, the profit maximisation is given by equation 47.The first term represents the income result from sales ( ௥߭) minus the productioncosts ( ௥ܿ ), the second and third term represents the operating costs due to anactive storage request for the excess amount of resource ݎ at each time event( ௥ܿ௦௧) and the cost of intermediate changeover/setup-up procedures required in-between different tasks i and i’ ( ௜ܿ,௜ᇲ௖௛), and the last terms are related to the disposalcost ( ௥ܿௗ) of extended shelflife products and backlog penalties cost ( ௥ܿ௨) ofunfulfilled demand. All costs are in “relative monetary units” (rmu).
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݉ ܽݔ
⎣
⎢
⎢
⎢
⎡
෍ ෍ ෍ ( ௥߭− ௥ܿ)(−Π௥,௟,௧)
௧∈்,௧வଵ௟∈௅ೝ௥∈௉
− ෍ ෍ ෍ ( ௥ܿ௦௧ܴ௥,௟,௧
௧∈்௟∈௅ೝ
) − ෍ ෍ ෍ ( ௜ܿ,௜ᇲ௖௛ܥ௜,௜ᇲ,௧
௟∈௅೔
)
௜ᇲ∈ூೝ
௜ᇲஷ௜
௜∈ூೝ௥∈ெ ೞ೟
− ෍ ෍ ෍ ௥ܿ
ௗܹ ௥,௟,௧
௧∈்
௧வଵ
௟∈௅ೝ௥∈ெ /ோெ − ෍ ෍ ෍ ௥ܿ௨Π௥,௟,௧௨௧∈்
௧வଵ
௟∈௅ೝ௥∈௉
⎦
⎥
⎥
⎥
⎤
(47)
4 ILLUSTRATIVE EXAMPLESIn this section, considering the mathematical formulation composed by equations 3 to 47,three planning/scheduling optimisation problems in a biopharmaceutical industrial plantare presented to explore the different model features. The examples were adapted fromthe operational parameters provided by Lakhdar et al. (2005), which is based on realindustrial data and covering the most common aspects of biopharmaceuticals’ production.All models were implemented using GAMS (GAMS 24.4.3 WIN VS8 x86) and solved withCPLEX running on an Intel Xeon ES-2660 v3 at 2.60 GHz with 64 GB of RAM.
4.1 Example IThe first example considers a mid-term planning problem in the biopharmaceuticalindustry adapted from Lakhdar et al. (2005): a two-stages facility composed by twoupstream fermentation suites [J1 & J2] and two downstream purification suites [J3 & J4]per stage, to manufacture products P1, P2 and P3 in a continuous production mode(Figure 5). The demand profile considers a total of 34 batches to be delivered in a set ofcampaign-lots in five delivery dates for a 360 days production horizon H (Table 1),assuming that late deliveries are penalised. For the profit maximisation, the problemconsiders: the total sales and the costs of manufacturing, storage, changeover/setup anddisposal. The time related to sequence independent changeover/setup procedures wasdetermined based in the product lead time provided in the example by Lakhdar et al.(2005). The remaining data used in the formulation, including manufacturing rate,minimum campaign length and product lifetime, is summarised in Tables 2a and 2b. Theterm “batch” in the data parameter, in order to reproduce the original problem statement,was assumed to correspond to a fix undisclosed amount due to confidentiality reasons. Tocomply with processes requirements, the blending of lots of intermediates is allowed(equation 15), the changeovers in downstream units are set to occur only at the beginningof the time interval (equations 29 and 31), the given production rates corresponds toequipment maximum specs, and unlimited storage capacity is assumed with no zero waitpolicies. Furthermore, in order to compare the the results obtained by Lakhdar et al.(2005), the scheduled batch tasks are set to last only one time interval (∆ݐ= 1) andrestrictive storage constraints given by equations 36 and 37 were disregarded.
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Figure 5 – RTN production layout for Example I
Table 1 – Demand profile for Example I
Product Total Demand
(batch)
Due dates (days)d1120 d2180 d3240 d4300 d5360P1 12 6 6P2 6 6P3 16 8 8
Table 2a – Main parameters for Example I
Manufacturing
rate - max
(batch/day)
Sequence-Dep.
Changeover time
(days)
Minimum
campaign length
(days)
Stored material
lifetime (days)
Storage cost
(rmu/
batch.event)
Waste disposal
cost (rmu/
batch)
Changeover
cost (rmu)I1 I2 I3I1 0.05 (10) 10 10 20 60 5 5 1I2 0.045 10 (10) 10 22 60 5 5 1I3 0.08 10 10 (10) 12.5 60 5 5 1P1 P2 P3P1 0.1 (30) 32 24.5 10 180 1 5 1P2 0.1 30 (32) 24.5 10 180 1 5 1P3 0.1 30 32 (24.5) 10 180 1 5 1
Table 2b– Main parameters for Example I
Manufacturing
cost (2 steps)
(rmu/ batch)
Sales price
(rmu/
batch)
Lateness penalty
(rmu/ batch)
Production
factor
ࣅ࢏,࢘P1 4 20 20 1P2 4 20 20 1P3 4 20 20 1
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4.1.1 Example I resultsThe computational results for the optimal schedule are presented in Table 3. Sincein a continuous time formulation the number of time events must be defined basedon the analysis of the problem, the first attempt considered 6 event points. This itis the minimum allowed by the model, since there are 5 delivery time events plusthe initial time point t0. Although, it was insufficient for the total on-time fulfilmentof the plan (profit 278 rmu, mostly penalised by late deliveries), but with 7 eventpoints the demand is totally satisfied without penalties or waste disposal costs, foran optimal profit of 513 rmu. The results for 8 and 9 event points are shown butwithout any solution improvement, which is coherent with the proposed stoppingcriteria to deliver the solution when the increment in the number of event points isnot accompanied by an increment in the objective function. In practice, sinceequation 10 does not allow the repetition of absolute time events, the solution isforced to create additional time intervals which can incur in profit penalties.
Table 3 – GAMS model results
Event
Points
Discrete
variables
Total
variables
Equations
Objective
MILP
CPU (s)
Optimality
Gap (%)6 3931 5638 6649 278 1.8 0.07 5237 7361 8898 513 27.8 0.08 6723 9300 11459 513 390.1 0.09 8389 11455 14332 511 2142.5 0.0
Considering the 7 event points solution, the Gantt chart of Figure 6 presents theoptimal sequencing and allocation of the different processing tasks in each of theprocessing suites, identifying: lot number and integer campaign size of eachintermediate/product manufacturing task (amount in brackets); thechangeover/set up requirements when different products are processed in thesame unit (identified by [CO] symbol); and the products’ storage allocation(identified by [S] symbol). Due to different processing rates, the tool developed togenerate the Gantt chart considered that the end of each downstream task is neverlower than the end of precursor upstream task. The results exhibit, for example,that 4 lots of I1 and 3 lots of P1 are produced: lot L3 of P1 (P1L3) is scheduled inunit [J4] during the time event interval [300,360] by the blending of lots L3 and L4of I1. Also, a single lot L1 of I1 scheduled to unit [J1] generates a single lot of P1L1 inunit [J4] during time event interval [120,180]. In this last case, the amount of lot L1of P1 produced is being stored till the third delivery date (d3) on the 240th day. Sixstorage tasks are active in the planning horizon to store 5 lots of final products(until the due dates are met) and 1 lot of intermediary product I3, which can bedetailed in the production inventory profile in Figure 7. These charts also verifythat, on the 240th day, lot P1L1 (stored since the previous interval) and theproduced lot P1L2 totals 6 bathes delivered (indicated with a triangle symbol)corresponding to the due date d3 demand. Recall that in this example, each storagetask is only active for the following time interval when the material resourceexcess is verified, according to equation 35. Regarding equipment changeovertasks, ten transfer cleaning/set-up procedures are required. Following the originalproblem statement by Lakhdar et al. (2005), the same set-up time was assigned foreach first campaign scheduled. As noted, the changeover time for the upstream
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units are allocated as suitable to either the beginning or end of the time slots,allowing the improvement of the duration/size of production tasks scheduled.Considering the utilisation rate of each equipment suite for the given horizon, it isverified that the upstream process is the limiting step due to its higher processingtimes, obtaining a 80% and 96% utilisation rate in J1 and J2, respectively, whiledownstream suites J3 and J4 present 55% and 71% rate, respectively.
Figure 6 – Gantt chart for Example I (7 event points): e.g. L1 of I3 scheduled in time interval [0,64.5] to
produce (4) batches; CO-changeover/set-up task assignment; S-storage allocation; d#-due date.
(Solution: 513 rmu)
Figure 7 – Material resources inventory profile for Example I [(S] and [triangle] symbols identify,
respectively, the storage allocation and the product amounts deliveries at due dates (d#))
M.Vieira et al.
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4.1.2 Results comparison with Lakhdar et al. (2005) modelThe mid-term planning problem here presented was originally addressed byLakhdar et al. (2005), which proposed a MILP model with a 60 days discrete-timeformulation to determine the optimal production schedule assuming a continuousprocessing upstream/downstream flow. The Gantt chart of Figure 8 and theproduction inventory profile in Figure 9 display the results obtained. In Table 4 theGAMS results are compared with our model solution with 7 event points in threedistinct scenarios.
Figure 8 – Gantt chart for Example I using Lakhdar et al. (2005) discrete time formulation (Solution:
490 rmu)
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Figure 9 – Material resources inventory for Example I using Lakhdar et al. (2005) discrete time
formulation
Table 4 – GAMS model results for Example I
Discrete
variables
Total
variables
Equations
Objective
MILP
CPU (s)
Optimality
Gap (%)Lakhdar et al. (2005) 252 457 499 490 0.3 0.0Proposed model- 7 time events 5237 7361 8898 513 27.8 0.0Proposed model for asingle lot index- 7 time events 539 1601 2163 513 2.2 0.0Proposed model using acontinuous batch-extentvariable- 7 time events 1709 7361 8898 519 46.9 0.0
The extent in number of variables and equations differ widely when comparing thediscrete time model with our proposed continuous-time formulation, mostly due
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to RTN framework and the additional features included, such as the lot trackingnot addressed by Lakhdar et al. (2005). For a simplified comparison exercise ofthe two models, in Table 4 is also shown the solution statistics if the lot featureswere disregarded (constraints [20-22]), suggesting a significant reduction incomputational complexity. Nevertheless, our solution schedule is able to providean improved objective profit in +23 rmu (4.7%). The profit result of the discretetime model is mostly penalised by the unfulfilled delivery of 1 batch of P1 due atthe 240th day (Figure 9). And although with one less changeover/set-up tasksscheduled, it presents additional storage costs of intermediate materials (I3 in thefirst and fourth time interval). Must be refereed that the discrete-time modelpresents a different estimate of the storage costs, but since both solutions show thesame number of time intervals it can be disregarded. Indeed, the solutionimprovement is verified because the continuous-time model flexes the duration ofthe first time interval to 64.5 days (the remaining events were allocated to duedates), while the discrete-time model fixes all intervals length in 60 days, a timedifference sufficient enough that allows to manufacture 4 batches of P3 in the firsttime slot to match demand on time. It was also verified that this model presentssome limitations in the assignment of changeovers (demanding that at most oneproduct undergoes manufacturing in any given intermediate time period) or in theimplementation of a shorter discretization of the time horizon.It must be noted that, to follow the original scheduling problem statement andperform a fair comparison with the results presented by Lakhdar et al. (2005), theextent variable ߦ௜௟௧௧ᇲ (that determines the amount of batches produced in eachscheduled campaign-task) was also set as an integer variable. As expected, if thescheduling problem unrestraint the campaign-extent size to any non-integernumber which, it can generate additional savings in the optimal profit by reducingthe costs of stored products. Figure 10 illustrates this aspect, depicting a similarschedule solution but now the optimal profit increases to 519 rmu, mainly due toavoid the storage costs of intermediary I3. For example, the schedule of non-integer task campaigns allows that the amount stored of final products in t=120days is equal to 3,7 batches (P2[L1&L2]), while in the previous solution the storedamounts is 4 batches.
Figure 10 – Gantt chart for Example I (7 event points) considering the extent variable ߦ௜௟௧௧ᇲas a positive
continuous variable (Solution: 519 rmu)
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4.2 Example IITo further demonstrate the model features, in this second example we are considering analternative campaign planning problem for a shorter demand period of 240 days withthree delivery dates, 6Kg of P1, 6Kg of P2 and 8Kg of P3, shown in Table 5. As displayed inFigure 11, the hybrid production process is now composed by one upstream stage thatoperates in a batch mode (Stage I), followed by two downstream continuous process steps,an ultrafiltration (Stage II) and a chromatography (Stage III) step, each stage composed bytwo identical processing suites. The operational data, presented in Table 6a and 6b, wasadapted from provided industrial data. For this case, different sequence-dependentchangeover times were defined for Stage 2 units for the process combinations possible(F1F2F3) and batch tasks are subject to equipment volume limitations. The samepremises stated in Example I are followed, with the exception that the extent task variable
ߦ௜௟௧௧ᇲ is not limited to integer amounts and all restrictions for storage tasks are applied(equations 36 and 37), which tightens the formulation for the lifetime limitations ofbiomaterials. Regarding the blending of lots of intermediaries, two situations are going tobe explored, considering for the initial approach that all is allowed. Finally, based on apreliminary analysis of processing times, the maximum duration of all batch tasks was setto two time intervals (οݐൌ )ʹ.
Figure 11 –Production layout for example II
Table 5 – Demand profile for Example II
Product Total Demand
(kg)
Due dates (days)d1100 d2180 d3240P1 6 6P2 6 6P3 8 8
R1R2R3
I1
I2
I3
F1F2
F3
J1
J2
J3
J4
Raw Materials Stage I Intermediaries I Stage II Intermediaries II Stage III Final products
P1
P2
P3
J5
J6
(Continuous) (Continuous)(Batch)
UPSTREAM DOWNSTREAM
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Table 6a – Main parameters for Example II
Manufacturing time –
 (day/kg)
Sequence-dep.
Changeover time (days)
Equipment
capacity max
(kg)
Stored
material
lifetime (days)
Storage cost
(rmu/
kg.event)
Waste
disposal cost
(rmu/ kg)
Changeover
cost (rmu)I1 I2 I3I1 18 (10) 10 10 5 60 5 5 1I2 20 10 (10) 10 5 60 5 5 1I3 12.5 10 10 (10) 5 60 5 5 1
Manufacturing
rate – max
(kg/day) F1 F2 F3 Minimumcampaign length(days)F1 0.22 (10) 35 20 4,5 120 1 5 1F2 0.2 16 (10) 30 5 120 1 5 1F3 0.25 18 22 (10) 4 120 1 5 1P1 P2 P3P1 0.2 (30) 32 24.5 5 120 1 5 1P2 0,2 30 (32) 24.5 5 120 1 5 1P3 0.2 30 32 (24.5) 5 120 1 5 1
Table 6b – Main parameters for Example II
Manufacturing
cost (3 steps)
(rmu/kg)
Sales price
(rmu/kg)
Lateness penalty
(rmu/kg)
Production
factor
ࣅ࢏,࢘P1 6 20 20 1P2 6 20 20 1P3 6 20 20 1
4.2.1 Example II resultsTable 7 reveals the results of the solution iteration for a set of time events, whichthe optimal solution is verified with 7 events for a profit of 268 rmu, since with 8events no solution improvement is verified. In the first iteration with 4 time events(three due dates plus the initial ݐൌ Ͳ), the profit solution is highly penalised withunfulfilled demand costs, seeing that the short number of time intervals is evenmore noticeable with this example, since a sequence of a batch and a continuoustask requires, at least, two time intervals to accomplish the production of a certainamount. Since tasks in stage I are processed in batch mode, the producedintermediaries are only made available for the following stage after the end of thetask, while continuous tasks of stages II and III occur simultaneously. The optimalplanning is presented in the Gantt chart of Figure 12, outlining the sequencing,allocation, storage and changeover requirements for the campaign lots in each ofthe processing suites. Twelve equipment changeover/setup tasks are required andonly one storage task is active for P1. Figure 13 resumes the production profile ofStage I intermediaries and final products, fulfilling the total demand on predefineddue dates. It can be verified that the optimal solution considers that campaignsI2L1, I2L2 and I1L1 are scheduled to widen for two consecutive time intervals, amodel feature that improves the flexibility of the solution results, while preserving
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computational hindrance, with relevance for this type of single-time grid horizonapproaches.
Table 7 – GAMS model results for Example II
Event
Points
Discrete
variables
Total
variables
Equations
Objective
MILP
CPU (s)
Optimality
Gap (%)4 5087 4210 5087 -121.1 0.5 0.05 1961 6059 7735 122.8 3.2 0.06 2565 8196 10851 214.6 39.8 0.07 3223 10621 14435 268.0 101.8 0.08 3935 13334 18487 268.0 1509.2 0.09 4701 16335 23007 267.0 3600.0 1.0
Figure 12 – Gantt chart for Example II with 7 event points (Solution: 268 rmu)
Figure 13 – Material resources inventory for Example II
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It can be also verified in Figure 12 that suite J4 is not used, since the productionrates in Stage II are sufficiently fast to process both Stage I lots of allintermediaries in the same unit. However, this is only possible because theblending/splitting of lots are allowed. Therefore, if we consider the case subject toregulatory purposes that the blending of Stage I intermediaries is forbidden (stillallowed for intermediaries II), the new solution for 7 time events given in Figures14 and 15 It can be verified that unit J4 is now required and it allows to follow thetrack record of the different lots throughout the units allocation of the productionprocess. The optimal profit solution is now 265,3 rmu, penalised by the additionaltwo changeover/set-up requirements and additional storage costs with P1L1 at 218days. As previously mentioned, the importance of regulatory requirements isstrictly important in all aspects of pharmaceutical manufacturing, where therelevance of lot traceability plays an important role to comply with an optimalscheduling solution. As reference, in these examples it was assumed that the modelfreely assigns the number of sequential lots and sizes, but the formulation alsoallows the cases where a specific set of lot sizes are requested (equation 23a).
Figure 14 – Gantt chart for Example II with 7 event points, assuming no blending of Stage I intermediaries’ lots
(Solution: 265,3 rmu, 0% optimality gap, after 466s)
Figure 15 – Material resources inventory for Example II, assuming no blending of Stage I intermediaries’ lots
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4.3 Example IIIIn this third example, we address a more detailed process layout for the manufacturing ofthree biopharmaceutical products P1, P2 and P3, by disaggregating theupstream/downstream production suites into five main operations. The productionsequence, as displayed in Figure 16, is composed by two batch stages for upstreamprocessing (cell fermentation and clarification), and for downstream processing, the twofirst stages operate in a continuous mode while the last in batch mode (centrifugation,ultrafiltration and chromatography). The problem considers 9 equipment units and task-unit suitability is verified for intermediaries of P1 on the first upstream stage, as I1 canonly be processed in unit J1 due to regulatory policies. In Table 8 is defined the demandprofile with 3 due dates, and the remaining operational data, presented in Table 9a and 9b,was adapted from provided industrial data (different selling prices of final products werenow considered). The same premises stated in Example II are followed, except that in thiscase the maximum duration of all batch tasks was assumed to last one interval (οݐൌ ͳ).
Figure 16 –Production layout for example III
Table 8 – Demand profile for Example III
Product Total Demand
(kg)
Due dates (days)d180 d2110 d3150P1 2 2P2 2 2P3 2 2
G1
G2
G3
F1F2
F3
J3
J4
J5
J6
Raw Materials Stage I Intermediaries I Stage II Intermediaries II Stage III Intermediaries III Stage IV Intermediaries IV Stage V Final products
K1
K2
K3
P1P2
P3
J7
J8
J9
(Continuous) (Continuous)(Batch) (Batch)
UPSTREAM DOWNSTREAM
R1R2R3
I1
I2
I3
J1
J2
(Batch)
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Table 9a – Main parameters for Example III
Manufacturing
time – (day/kg)
Sequence-dep.
Changeover time (days)
Equipment
capacity max
(kg)
Stored
material
lifetime (days)
Storage cost
(rmu/
kg.event)
Waste
disposal cost
(rmu/ kg)
Changeover
cost (rmu)I1 I2 I3I1 10 (10) 10 10 5 60 5 5 1I2 12 10 (10) 10 5 60 5 5 1I3 6.5 10 10 (10) 5 60 5 5 1F1 F2 F3G1 5 (20) 3 20 4 120 5 5 1G2 4 16 (20) 35 4 120 5 5 1G3 4.5 18 22 (20) 4 120 5 5 1
Manufacturing
rate – max
(kg/day) F1 F2 F3 Minimumcampaign length(days)F1 0.2 (15) 15 15 5 120 1 5 1F2 0.25 15 (15) 15 5 120 1 5 1F3 0.28 15 15 (15) 5 120 1 5 1
Manufacturing
rate – max
(kg/day) F1 F2 F3 Minimumcampaign length(days)K1 0.32 (10) 18 18 5 120 1 5 1K2 0.3 18 (10) 18 5 120 1 5 1K3 0.28 18 18 (10) 5 120 1 5 1
Manufacturing
time – (day/kg) P1 P2 P3P1 6 (30) 32 24.5 5 120 1 5 1P2 8 30 (32) 24.5 5 120 1 5 1P3 4.5 30 32 (24.5) 5 120 1 5 1
Table 9b – Main parameters for Example III
Manufacturing
cost (5 steps)
(rmu/kg)
Sales price
(rmu/kg)
Lateness penalty
(rmu/kg)
Production
factor
ࣅ࢏,࢘P1 10 30 20 1P2 10 38 20 1P3 10 25 20 1
4.3.1 Example III resultsWith this industrial problem, the main goal was to discuss the model performanceconsidering a production layout with a set of 5 process steps, acknowledging thegenerality of the model formulation with its different model features. In Table 8 is shownthe solution iteration for each number of time events, to reach the optimal planningsolution presented in the Gantt chart of Figure 17 (106 rmu for 8 time events). It showsthe size/duration, sequencing, allocation, storage and changeover requirements for thecampaign lots in each processing unit, with the flow sequence of batch and continuoustasks. Although, it requires additional time events to accomplish a complete productionsequence, and for this reason, the first results of the solution iteration of Table 8 are
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penalised. The profit results for 9 and 10 time events were also penalised due to extrastorage costs. In the Gantt chart of Figure 17 is it possible to follow the scheduleassignment of the different tasks and units throughout each production stage ofintermediaries, able to comply with the deliver of two batches of each product on the 80th,110th 150th day. It was assumed that the blending of lots in upstream stages was notallowed due to regulatory policies, but it can be verified at stage III, where two lots of F1originate one of K1, as also the splitting of one lot of K2 to originate two lots of P2 at thefinal stage. The flexibility to schedule the changeover/set-up time and the blending of lotshas proven to allow an improved allocation of the different tasks to the planning horizon.However, it was noted the computational complexity increase with the problem data set,which is a criterion in our research as a requirement to provide an operational decision-support tool for industrial environments.
Table 10 – GAMS model results for Example III
Event
Points
Discrete
variables
Total
variables
Equations
Objective
MILP
CPU (s)
Optimality
Gap (%)
4 3318 7413 7877 -249 0.3 0.05 4443 12023 11483 -152 1.4 0.06 5658 16947 16263 - 41 4.9 0.07 6963 17727 22649 15 82.1 0.08 8358 22017 29129 106 95.2 0.09 9843 26733 36387 103 563.2 0.010 11418 31875 44423 101 1792.5 0.0
Figure 17 – Gantt chart for Example III with 8 event points, assuming no blending allowed of upstream
stages intermediaries’ lots (Solution: 106 rmu)
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5 CONCLUSIONSIn this work a MILP formulation, based on a RTN continuous-time single time-gridformulation, was developed to solve the campaign planning/scheduling problems ofbiopharmaceutical processes. Acknowledging a fairly unexplored topic, the work wasfocused in addressing specific constraints of these biochemical processes not yetcombined, which included the modelling of batch and/or continuous process steps,multiple intermediate deliveries, sequence dependent operations, storage of productsregarding shelf-life limitations, and the track-control of the production lots for regulatorypolicies. The developed model was applied to three examples with different productionlayouts: the first example considered a mid-term planning problem representing the twomain stages (upstream/downstream) of biopharmaceutical processes; the second examplediscussed additional model features onto a hybrid production process with three batchand continuous stages; and the third example extended the production layout consideringthe five main processing steps. Based on different industrial data sets and demandprofiles, the model was able to solve the optimal schedule for each problem, providing thesequencing and allocation of the different processing units, the track record of campaign-lot quantities for each intermediate/product, the sequence-dependent changeoverrequirements and storage allocations. The results of the first example were compared witha discrete-time model, originally presented by Lakhdar et al. (2005), and discussed theadvantages of the proposed continuous-time formulation in the duration/extent ofscheduled campaign-tasks in order to fulfil the production demand.As main conclusion, this work resumes a generic formulation to address the maincampaign planning/scheduling challenges of biopharmaceutical processes. The RTNcontinuous time model was proven to be effective to solve the proposed industrialproblems, particularly sensitive to changes in the tasks duration. Further research workwill address alternative time-grid formulations to enhance computational performanceinto the complexity of real biopharmaceutical production processes, understanding thediverse model approaches and scalability. Some modelling aspects to overcome in futureworks are associated with the robustness of the storage features between batch andcontinuous tasks, the related control of shelf-life time constrains of stored materials, andthe integration of operational parameters uncertainty to replicate real process variability.
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NOTATION
Indices
݀ delivery dates,݅ ′݅ task
݈ lot
ݎ resource (process unit, intermediate or final product)
ݐ,ݐᇱ,ݐᇱᇱ,ݐᇱᇱᇱ event point
SetsB resources in which lots are allowed to be blended
ܦ delivery dates
ܦ௥ delivery dates associated with resource r
ܧ processing equipment
ܧ௦௧ subset of equipment related to storage
ܫ process tasks
ܫ௥ tasks that require resource r
ܫ௕ batch tasks
ܫ௖ continuous tasks
ܫ௦௧ storage tasks
Izw tasks subject to zero-wait policies
Imr tasks that must exceed a certain minimum rate
ܫ௥஻஼
௖ subset of continuous tasks that consumes the intermediatematerial r produced by a batch task
ܫ௦௧
஻ ,ܫ௦௧஼ ,ܫ௦௧ூே்_஼ subset of storage tasks related to intermediates and finalproducts produced by batch and continuous tasks
ܫ௥
௦௧ storage tasks associated with material resource r
ܮ lots
ܮ௥ lots associated with resource r
ܮ௜ lots associated with task i
ܮ஻
௥ lots of resource ݎ∈ ܤ that are able to be blended
ܯ material resources
ܯ௦௧ subset of material resources able to be stored
ܲ subset of final products
ܴ process resources
RM subset of raw material resources
ܶ event points
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Parameters
ߙ௜ constant term in the processing time of task I
ߚ௜ proportional term to the extent variable in the processingtime of task I
ߤ௜,௥௖ allocation coefficient for the binary extent of resource r(equipment unit) in task I relative to the start of the task
ߤ௜,௥௣ release coefficient for the binary extent of resource r(equipment unit) in task I relative to the end of the taskprocessing time of task k
ߥ௜,௥௖ consumption coefficient for the continuous extent of rresource (intermediary or final product) in task I relative tothe start of task
ߥ௜,௥௣ production coefficient for the continuous extent of resource r(intermediary or final product) in task I relative to the end oftask
ߣ௜,௥ coefficient for the rate of consumption of resource r by task i
௥ܿ cost of manufacturing resources r
௥ܿ
௨ backlog penalties cost
௥ܿ
ௗ waste disposal cost
௜ܿ
௦௧ storage cost
௜ܿ,௜ᇲ௖௛ sequence dependent {I,i’} changeover cost
௥߭ sales of resource r
ܪ time horizon
ℎௗ absolute time of demand point d
δ௜,௜ᇲ time relative to task sequence changeover {I,i’}
ߪ௜,௟. lifetime of the processed products of the task I lot l
ܥܽ݉ ݌௜,௟. minimum campaign length of the processing task I lot l
ߩ௜
௠ ௜௡,ߩ௜௠ ௔௫ minimum and maximum allowable rate of task i
ܳ௥,ௗ௠ ௡ , ܳ௥,௟,ௗ௠ ௔௫ minimum and maximum amount of resource r of one lot l atdelivery d
ܳ௥,ௗ demand amount of each resource at delivery date d
ܴ௥
଴,ܴ௥,௟଴ resource availability in the beginning of the planning horizon
ܴ௥
௠ ௔௫ maximum resource availability of resource r
∆t maximum number of consecutive events points allowed forbatch tasks
௜ܸ,௟௠ ௜௡, ௜ܸ,௟௠ ௔௫ minimum and maximum capacity of resource r (processingunits) for task I of lot l
Variables
ܥ௜,௜ᇲ,௧,ܥ௜,௜,௧ binary variable that assigns a sequence dependentchangeover procedure to task i before time event t
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ܰ௜,௟,௧,௧ᇲ binary variable that assigns the task i of lot l to start at eventpoint t and ended until point t’
ߦ௜,௟,௧,௧ᇲ total amount of material processed by task i and lot l withinthe event interval [t,t’]
ܴ௥
௜௡௜௧ allocation of resource r (processing units)at the beginning ofthe scheduling horizon
ܴ௥,௟,௧ resource availability r of lot l and time point t
ܴ௥,௟,௧௖ ,ܴ௥,௟,௧௣ amount consumed/produced of resource r of lot l and timepoint t
௜ܵ,௟,௧,௧ᇱ binary variable that accounts when the product lifetimestored through task i lot l was extended within the interval[t,t’]
ݔ௜,௟,௧,௧ᇲ accounts for the absolute storage time if storage task i lot l isactive in the event interval [t,t’]
ܹ ௥,௟,௧ waste disposal amount when resource shelf-life is exceeded
௧ܻ,ௗ binary variable that assigns a specific event point tcorresponds to a demand points d
Π௥,௟,௧ amount expedited at a corresponding due date
Π௥,௟,௧௨ unfulfilled demand of product r of lot l
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